Stevanato Group Reports 7% Q1 Revenue Growth, 10% at Constant Currency
Stevanato Group’s revenue in the first quarter of fiscal 2026 rose by 7% year-on-year and by 10% at constant currency. This marks continued top-line expansion for the packaging specialist early in its 2026 financial year.
1. Q1 Fiscal 2026 Revenue Performance
Stevanato Group posted a 7% increase in total revenues for the first quarter of fiscal 2026 compared with the year-ago period. This growth reflects ongoing demand for its pharmaceutical packaging solutions at the start of the new fiscal year.
2. Constant Currency Gains
Excluding the impact of foreign exchange fluctuations, the company’s revenues climbed by 10% on a constant currency basis, underscoring stronger underlying sales trends.
3. Business Momentum
Stevanato Group’s early fiscal performance reinforces its market position in injectable drug delivery products, setting a positive tone for the remainder of its 2026 financial year.